Trent Webb
About Trent Webb
W. Trent Webb is President, American Group at Surgery Partners and has been with the company for ~15 years; he became American Group President in September 2024, is 45 years old, and holds a BBA and MAcc from the University of Tennessee . Company performance under the current leadership team in 2024: revenues rose 13.5% to $3.11B and Adjusted EBITDA increased 16.0% to $508.2M, providing the backdrop for incentive plan outcomes . The 2024 cash incentive design weighted Adjusted EBITDA 70%, Net Revenue 15%, and Free Cash Flow 15%, with payouts ultimately below target and partially settled in restricted stock .
Past Roles
| Organization | Role | Years | Strategic Impact |
|---|---|---|---|
| Surgery Partners | Senior Vice President, Operations – Central Region | Not disclosed | Led regional operations immediately prior to appointment as American Group President |
| Surgery Partners | Operations and Finance leadership roles | Not disclosed | Broad, multi-functional operating and finance experience over 15 years with the company |
External Roles
| Organization | Role | Years | Strategic Impact |
|---|---|---|---|
| Ernst & Young LLP (Nashville) | Auditor/Consultant focused on acute care healthcare clients | 7 years | Healthcare-focused financial and controls expertise prior to Surgery Partners |
Fixed Compensation
- No executive-specific base salary, target bonus %, or perquisites are disclosed for Trent Webb in the latest proxy statement. The Compensation Committee maintains a well-balanced program with cash and equity, limited perquisites, hedging prohibitions, and an executive compensation recovery (clawback) policy .
Performance Compensation
| Metric | 2024 Weighting | 2024 Target | 2024 Actual | Payout Notes |
|---|---|---|---|---|
| Adjusted EBITDA ($mm) | 70% | $510.0 | $508.2 | Awards paid below target; a portion settled in time-based restricted stock vesting in 1 year |
| Net Revenue ($mm) | 15% | $3,063.0 | $3,110.0 | Same payout approach as above |
| Free Cash Flow ($mm) | 15% | $150.0 | Below threshold | No payout for FCF portion below threshold |
-
Group Presidents’ annual cash incentives incorporate 50% company metrics and 50% group-specific goals; the group-specific component must reach at least 25% of target to earn any payout .
-
Long-term incentives under the plan use a mix of time-based restricted stock (typically vesting ratably over 3 years) and PSUs that cliff vest after three years based on achieving multi-year Adjusted EBITDA goals, with up to 300% payout and a TSR modifier (10–20% depending on grant year) .
Equity Ownership & Alignment
- Hedging prohibited across employees, officers and directors; insider trading policy restricts derivatives or transactions designed to offset declines in Company stock .
- Share ownership and retention guidelines apply to NEOs and non-employee directors (CEO: 5× salary; other NEOs: 3×; directors: 5× retainer). The proxy does not explicitly extend these guidelines to non-NEO executive officers like Webb .
Historical ownership snapshot (2015, pre-current role):
| Item | Value | Source |
|---|---|---|
| Ownership % (Annex A) | 0.04% | |
| Unvested Class B Units | 27,410 | |
| Restricted Common Stock (Surgery Partners, Inc.) | 6,150 shares |
Note: The above holdings are from a 2015 filing and may have changed materially; no current beneficial ownership for Webb is disclosed in the 2024–2025 proxies .
Employment Terms
- Equity award terms (Company-wide plan): RSAs typically vest ratably over 1–3 years; PSUs have a performance period (often one year of achievement with subsequent vesting over two years or a three-year cliff) and can pay from 0% to 300% based on performance and market/TSR modifiers; accelerated vesting of earned shares can occur upon certain terminating events, including change in control .
- Change-in-control protections emphasize double-trigger for options and restricted stock; PSUs earned as of the change-in-control date may continue to vest based on time, or accelerate if not assumed .
- NEO severance (illustrative of Company practice): 12 months base salary, target bonus, and continued health and welfare benefits; COBRA and timing vary by executive, with lump-sum if within the change-in-control window .
- Restrictive covenants: 1-year non-compete and 2-year non-solicitation for NEOs; executive agreements include confidentiality and IP assignment provisions .
Investment Implications
- Alignment signals: Multi-year, performance-weighted LTI design with double-trigger CIC and an active clawback policy merit positive governance marks; hedging prohibitions reduce misalignment risk . 2024 say‑on‑pay support (~95%) indicates broad shareholder acceptance of pay design for named officers .
- Retention and execution: Webb’s 15-year tenure, cross-functional operations/finance background, and EY healthcare experience support domain execution capabilities . Group President incentives tied partly to group-specific metrics can sharpen execution accountability .
- Data gaps and monitoring: No current Form 4 data or proxy-reported ownership for Webb were available; attempts to fetch insider trades (Form 4) for Webb encountered an authorization error. We searched 8‑K Item 5.02 appointments/compensatory filings but found no disclosure naming Webb; monitor future 8‑Ks or proxies for employment agreement terms, grants, and ownership updates .